Important Updates

Updated 12/22/2023

NABP National News and Resources

National News

Important Updates​​

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain​

Fighting Fake Medicines Sold Online Requires Commitment to Cautioning Patients​ ​

NASCSA News - Announcing Free CE on Prescription Monitoring Programs Available​

Reporting Theft or Significant Loss of Controlled Substances​

Accidental Ingestion Information​

Tianeptine Now a Schedule I Controlled Substance in Kentucky​

Pharmacist CE Requirement 2023-2028: 1 Contact Hour on Opioid Epidemic or Opioid Use Disorder Required Each Year.​

USP Revisions 797 & 795: Public comment period now open for draft proposal of 201 KAR 2:076 compounding regulation.​

Health Alert: Counterfeit Pharmaceuticals (March 17, 2023)

Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act​

PCSC Warns of Additional Product Ordering and Recall Fraud Incidents
Appeals Panel Decisions on USP Compounding Standards

Important changes regarding butalbital containing products

DEA Rescheduling of Hydrocodone Combination Products - Impact on Kentucky Prescribers

Pharmaceutical Controlled Substance Disposal General Public Fact Sheet

Pharmaceutical Controlled Substance Disposal Long Term Care Facility Fact Sheet

Pharmaceutical Controlled Substance Disposal Registrant Fact Sheet December 22, 2014 Informational Bulletin

Ebola Guidelines

902 KAR 2_020. Reportable disease surveillance (Amended Regulation - TB Reporting)

Synthetic Cannabinoids April 2015

Restrictions on possession of dextromethorphan and sale of products containing dextromethorphan

Gabapentin - Schedule V Controlled Substance

Important Updates